Equities

Petros Pharmaceuticals Inc

PTPI:NAQ

Petros Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3515
  • Today's Change-0.024 / -6.32%
  • Shares traded97.31k
  • 1 Year change-79.01%
  • Beta2.3015
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments139.4324
Total Receivables, Net2.232.112.46
Total Inventory1.611.820.52
Prepaid expenses2.400.511.58
Other current assets, total0.820.802.14
Total current assets201531
Property, plant & equipment, net0.260.400.52
Goodwill, net------
Intangibles, net8.971225
Long term investments------
Note receivable - long term------
Other long term assets4.185.1111
Total assets343267
LIABILITIES
Accounts payable1.711.814.56
Accrued expenses7.463.6224
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.161.090
Other current liabilities, total0.440.552.88
Total current liabilities117.0731
Total long term debt6.868.390
Total debt8.019.480
Deferred income tax------
Minority interest------
Other liabilities, total3.690.260.87
Total liabilities211632
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital111107106
Retained earnings (accumulated deficit)(99)(91)(71)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity121736
Total liabilities & shareholders' equity343267
Total common shares outstanding2.992.082.07
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.